151 related articles for article (PubMed ID: 23951555)
1. Microenvironment-Dependent Phenotypic Changes in a SCID Mouse Model for Malignant Mesothelioma.
Darai-Ramqvist E; Nilsonne G; Flores-Staino C; Hjerpe A; Dobra K
Front Oncol; 2013; 3():203. PubMed ID: 23951555
[TBL] [Abstract][Full Text] [Related]
2. Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts.
Tsuji AB; Sogawa C; Sugyo A; Sudo H; Toyohara J; Koizumi M; Abe M; Hino O; Harada YN; Furukawa T; Suzuki K; Saga T
Nucl Med Biol; 2009 May; 36(4):379-88. PubMed ID: 19423005
[TBL] [Abstract][Full Text] [Related]
3. Blocking the GITR-GITRL pathway to overcome resistance to therapy in sarcomatoid malignant pleural mesothelioma.
Chan M; Wu L; Yun Z; McKee TD; Cabanero M; Zhao Y; Kohno M; Murakami J; de Perrot M
Commun Biol; 2021 Jul; 4(1):914. PubMed ID: 34312483
[TBL] [Abstract][Full Text] [Related]
4. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
[TBL] [Abstract][Full Text] [Related]
5. Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression.
Kojima M; Kajino K; Momose S; Wali N; Hlaing MT; Han B; Yue L; Abe M; Fujii T; Ikeda K; Hino O
Respir Res; 2020 Jul; 21(1):187. PubMed ID: 32677949
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of two distinct malignant mesothelioma cell lines with common clonal origin.
Schulten HJ; Perske C; Thelen P; Polten A; Borst C; Gunawan B; Nagel H
Cancer Genet Cytogenet; 2007 Jul; 176(1):35-47. PubMed ID: 17574962
[TBL] [Abstract][Full Text] [Related]
7. Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
Marqués M; Tranchant R; Risa-Ebrí B; Suárez-Solís ML; Fernández LC; Carrillo-de-Santa-Pau E; Del Pozo N; Martínez de Villarreal J; Meiller C; Allory Y; Blum Y; Pirker C; Hegedus B; Barry ST; Carnero A; Berger W; Jean D; Real FX
Cancer Res; 2020 Feb; 80(4):843-856. PubMed ID: 31911549
[TBL] [Abstract][Full Text] [Related]
8. Co-existence of epithelioid and fibroblastoid subsets in a sarcomatoid renal carcinoma cell line revealed by clonal studies.
Hsieh CH; Chen HC; Chang YH; Pang ST; Kuo ML; Chuang CK; Liao SK
Anticancer Res; 2013 Nov; 33(11):4875-89. PubMed ID: 24222125
[TBL] [Abstract][Full Text] [Related]
9. Three newly established immortalized mesothelial cell lines exhibit morphological phenotypes corresponding to malignant mesothelioma epithelioid, intermediate, and sarcomatoid types, respectively.
Sato T; Nakanishi H; Akao K; Okuda M; Mukai S; Kiyono T; Sekido Y
Cancer Cell Int; 2021 Oct; 21(1):546. PubMed ID: 34663305
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling.
Sun X; Wei L; Lidén J; Hui G; Dahlman-Wright K; Hjerpe A; Dobra K
J Pathol; 2005 Sep; 207(1):91-101. PubMed ID: 16007577
[TBL] [Abstract][Full Text] [Related]
11. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
[TBL] [Abstract][Full Text] [Related]
12. AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma.
Sudo H; Tsuji AB; Sugyo A; Abe M; Hino O; Saga T
Int J Oncol; 2014 Feb; 44(2):530-8. PubMed ID: 24253341
[TBL] [Abstract][Full Text] [Related]
13. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.
Kadota K; Suzuki K; Sima CS; Rusch VW; Adusumilli PS; Travis WD
J Thorac Oncol; 2011 May; 6(5):896-904. PubMed ID: 21358344
[TBL] [Abstract][Full Text] [Related]
14. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
Klebe S; Swalling A; Jonavicius L; Henderson DW
J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
[TBL] [Abstract][Full Text] [Related]
15. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
[TBL] [Abstract][Full Text] [Related]
16. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
Meyerhoff RR; Yang CF; Speicher PJ; Gulack BC; Hartwig MG; D'Amico TA; Harpole DH; Berry MF
J Surg Res; 2015 Jun; 196(1):23-32. PubMed ID: 25791825
[TBL] [Abstract][Full Text] [Related]
17. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
Prabhakaran S; Hocking A; Kim C; Hussey M; Klebe S
Hum Pathol; 2020 Nov; 105():1-8. PubMed ID: 32888937
[TBL] [Abstract][Full Text] [Related]
18. Pathohistological diagnosis and differential diagnosis.
Tischoff I; Neid M; Neumann V; Tannapfel A
Recent Results Cancer Res; 2011; 189():57-78. PubMed ID: 21479896
[TBL] [Abstract][Full Text] [Related]
19. The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura.
Chirieac LR; Pinkus GS; Pinkus JL; Godleski J; Sugarbaker DJ; Corson JM
Am J Cancer Res; 2011; 1(1):14-24. PubMed ID: 21969119
[TBL] [Abstract][Full Text] [Related]
20. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
